Statins are potential anticancerous agents (review).

@article{Altwairgi2015StatinsAP,
  title={Statins are potential anticancerous agents (review).},
  author={Abdullah K. Altwairgi},
  journal={Oncology reports},
  year={2015},
  volume={33 3},
  pages={
          1019-39
        }
}
  • A. Altwairgi
  • Published 1 March 2015
  • Biology, Chemistry
  • Oncology reports
Statins are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), which is a rate-limiting enzyme in the mevalonate pathway. The pleiotropic effects of statins may be mediated by the inhibition of downstream products such as small GTP-binding proteins, Rho, Ras and Rac whose localization and function are dependent on isoprenylation. Preclinical studies of statins in different cancer cell lines and animal models showed antiproliferative, pro‑apoptotic and anti-invasive effects… 
View on PubMed
spandidos-publications.com
97 Citations
Highly Influential Citations
2
Background Citations
32
Methods Citations
3
Results Citations
1

Figures and Tables from this paper

97 Citations

Citation Type

Citation Type

Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells
TLDR
Results indicate a resistance of cancer cells against statins, which is in part due to the induction of HMGCR.
Pleiotropic effects of statins: a focus on cancer.
Biocatalyzed Synthesis of Statins: A Sustainable Strategy for the Preparation of Valuable Drugs
TLDR
There is a growing interest in developing more sustainable protocols for preparation of statins, and the introduction of biocatalyzed steps into the synthetic pathways is highly advantageous—synthetic routes are conducted under mild reaction conditions, at ambient temperature, and can use water as a reaction medium in many cases.
Crosstalk between Statins and Cancer Prevention and Therapy: An Update
TLDR
Combining statins with histone deacetylase inhibitors can induce a synergistic anticancer effect, which is associated with a poor prognosis.
Anti-cancer properties of " hydrophilic and hydrophobic " statins and cyclin-dependent kinases
TLDR
The general QSAR equation: Transport or Inhibition = ΔG desolvation + ΔG lipophilicity + Dipole Moment + Molecular Volume is shown to apply to statin inhibition of HMG-CoA reductase, passive and active statin cellular transport, the inhibition of growth of pancreatic cancer cells, and the survival times of mice.
Statins: A Conceivable Remedial Role for the Regulation of Cancer Progression
  • G. Sherbet
  • Biology
    Current Cancer Therapy Reviews
  • 2019
TLDR
The wide spectrum of cancer associated events which these mevalonate inhibitors appear to influence would suggest a conceivable role for them in cancer management, but much deliberation is warranted in the design and planning of clinical trials, their scope and definition of endpoints, modes risk assessment and the accrual of benefits.
Identification of foods that affect the anti-cancer activity of pitavastatin in cells.
TLDR
Foods that patients could eat to potentially improve the outcome of clinical trials of pitavastatin in cancer are tested to identify those that affected the cytotoxic activity of pitvastatin towards ovarian cancer cells.
Exploitation of pleiotropic actions of statins by using tumour-targeted delivery systems
TLDR
This review summarises the possible pleiotropic actions of statins involved in tumour growth inhibition and presents an overview of the current status of targeted delivery systems for statins with possible utilisation in oncology.
Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer
TLDR
Pitavastatin-induced apoptosis was blocked by geranylgeraniol and mevalonate, products of the HMGCR pathway, confirming that pitvastatin causes cell death through inhibition of H MGCR, and diet should be controlled in clinical trials of statins.
The poor design of clinical trials of statins in oncology may explain their failure - Lessons for drug repurposing.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 141 REFERENCES
The statins as anticancer agents.
  • Kelvin K. W. Chan, A. Oza, L. Siu
  • Biology, Chemistry
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
TLDR
Potential future directions in the development of the statins as anticancer agents include combinations with chemotherapeutic or other molecular-targeted agents, combinations with radiotherapy, maintenance therapy in minimal disease status, and as chemopreventive therapy.
Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non‐small lung cancer cells
TLDR
Effects of either simvastatin or the farnesyl transferase inhibitor R115777 are evaluated on phosphorylation of the ERK1/2 group of mitogen‐activated protein kinases and on apoptosis, plus on cell numbers and morphology.
Cytotoxic effect of different statins and thiazolidinediones on malignant glioma cells
TLDR
The assessed combination of statins with thiazolidinediones shows a synergistic cytotoxic effect against glioblastoma cells in vitro, which could represent a feasible therapeutic schema.
Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study.
TLDR
The results suggest that cerivastatin inhibits cell signaling pathways involved in the invasiveness and metastatic properties of highly invasive cancers.
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial
TLDR
It is suggested that HMGCR is targeted by statins in breast cancer cells in vivo, and that statins may have an anti-proliferative effect in H MGCR-positive tumors.
HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway
TLDR
Results suggests that H MG-CoA reductase inhibitors induce lymphoma cells apoptosis by increasing intracellular ROS generation and p38 activation and suppressing activation of Akt and Erk pathways, through inhibition of metabolic products of the HMG- coenzyme A reduct enzyme reaction including mevalonate, FPP and GGPP.
Lovastatin inhibits tumor growth and metastasis development of a rat fibrosarcoma.
TLDR
It is demonstrated that a short treatment with LOV diminished primary tumor growth and the number and size of lung experimental metastasis and Lovastatin competitively inhibits HMG-CoA reductase, blocking the synthesis of mevalonic acid and the generation of non-sterol isoprenoids, such as farnesyl residues.
Mevalonate pathway is a therapeutic target in esophageal squamous cell carcinoma
TLDR
The findings suggest that the MVA pathway plays an important role in the progression of ESCC by modulating cell growth and statin might be a potential therapeutic agent in ESCC.
Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis.
TLDR
A novel action of LST is described that inhibited experimental lung metastasis of the highly metastatic B16F10 mouse melanoma in nude mice, identifying an antimetastatic agent with potentially useful clinical application.
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
  • A. Thibault, D. Samid, +9 authors C. Myers
  • Medicine, Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1996
TLDR
Treatment with ubiquinone was associated with reversal of lovastatin-induced myopathy, and its prophylactic administration prevented the development of this toxicity in a cohort of 56 patients.
...
1
2
3
4
5
...